
    
      This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety,
      tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active
      biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced
      solid tumors in Phase 1 and BA3011 alone and in combination with nivolumab in Phase 2.

      Phase 1 of this study will consist of a dose escalation phase (enrollment complete as of Oct
      2019) and a dose expansion phase (still enrolling).

      Phase 2 is targeted to begin in Q3 2020 and will include both adult and adolescents age 12
      and over.
    
  